Geron Corp - GERN STOCK NEWS

Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm specializing in hematologic malignancies, announced that Dr. John A. Scarlett will present a company overview at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 p.m. ET. The presentation will be available via a live webcast on Geron's Investor Relations website and archived for 30 days thereafter. Geron is currently conducting two Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) reported strong evidence of imetelstat's disease-modifying activity, targeting lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF). Key insights were presented at an Investor Event, highlighting significant unmet needs in these conditions. Geron plans three new clinical programs for imetelstat, including combinations with existing therapies, and anticipates peak revenue exceeding $3 billion in these indications. Financially, Geron reported a net loss of $26.7 million for Q3 2021, with cash reserves of $215.8 million expected to fund operations through early 2023.

Geron Corporation (NASDAQ: GERN) has announced that imetelstat, their first-in-class telomerase inhibitor, has received the Innovation Passport designation from the UK's MHRA under the Innovative Licensing and Access Pathway. This designation aims to expedite the regulatory review process, allowing a 150-day accelerated assessment for Marketing Authorization Applications. The IMerge Phase 2 study demonstrated durable transfusion independence in lower risk MDS patients. Geron is conducting two ongoing Phase 3 clinical trials for imetelstat.

Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options for 80,000 shares to new employees as an inducement to join the company. These options were issued on October 20, 2021, at an exercise price of $1.45 per share, matching the closing stock price on that date. The options have a 10-year term and will vest over four years. Geron is focused on developing a telomerase inhibitor, imetelstat, currently in two Phase 3 clinical trials for myeloid hematologic malignancies.

Geron Corporation has completed patient enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). Top-line results are anticipated in January 2023. Imetelstat, a first-in-class telomerase inhibitor, has shown promising results in Phase 2 trials, including durable transfusion independence in patients. The IMerge trial involves approximately 170 patients and aims to evaluate red blood cell transfusion independence. The company aims to address the significant medical need for alternative treatments in lower risk MDS patients.

Geron Corporation (Nasdaq: GERN) will hold a virtual investor event on November 9 at 4:00 p.m. ET. The event will address unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis, focusing on the potential of imetelstat, Geron's first-in-class telomerase inhibitor. Attendees will hear about expansion opportunities for imetelstat and can participate in a live Q&A with experts, including Dr. Swaminathan Iyer and Dr. John Mascarenhas. A webcast will be available on Geron's Investor Relations page, archived for 30 days.

Geron Corporation (Nasdaq: GERN) reported significant findings from its IMbark Phase 2 clinical trial for imetelstat, a treatment for refractory myelofibrosis (MF). Published in the Annals of Hematology, the study indicates that patients treated with imetelstat had a median overall survival (OS) of approximately 30 months, over double the 12 months for those receiving best available therapy. The ongoing IMpactMF Phase 3 trial aims to further validate these results. Imetelstat is noted for its potential to address unmet needs in patients unresponsive to JAK inhibitors.

Geron Corporation (NASDAQ: GERN) announced the granting of a non-statutory stock option for 400,000 shares of common stock to a newly hired employee. The option was awarded on September 15, 2021 with an exercise price of $1.36, matching the stock's closing price on that date. The option has a 10-year term, vesting in increments over four years, with 12.5% vesting after six months. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aligns with Geron’s 2018 Inducement Award Plan.